The global renal biomarkers market is estimated at USD 1.76 billion in 2025 and projected to reach USD 3.57 billion by 2034, growing at a CAGR of 8.22% from 2025 to 2034. Growth is driven by the increasing prevalence of kidney disorders, rising demand for early detection, and advancements in diagnostic technologies.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Renal Biomarkers Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Renal Biomarkers Market Revenue and Volume, by Biomarker
8.1.1 Functional Biomarker
8.1.1.1. Market Revenue and Volume Forecast
8.1.2. Up-regulated Protein
8.1.2.1. Market Revenue and Volume Forecast
8.1.3. Other Biomarker
8.1.3.1. Market Revenue and Volume Forecast
9.1. Renal Biomarkers Market Revenue and Volume, by Diagnostic Technique
9.1.1. Enzyme-linked Immunosorbent Assay
9.1.1.1. Market Revenue and Volume Forecast
9.1.2. Colorimetric Assay
9.1.2.1. Market Revenue and Volume Forecast
9.1.3. Particle-enhanced Turbidimetric Immunoassay (PETIA)
9.1.3.1. Market Revenue and Volume Forecast
9.1.4. Chemiluminescent Enzyme Immunoassay (CLIA)
9.1.4.1. Market Revenue and Volume Forecast
9.1.5. Liquid Chromatography Mass
9.1.5.1. Market Revenue and Volume Forecast
9.1.6. Spectrometry (LC-MS)
9.1.6.1. Market Revenue and Volume Forecast
10.1. Renal Biomarkers Market Revenue and Volume, by End-user
10.1.1. Hospital
10.1.1.1. Market Revenue and Volume Forecast
10.1.2. Diagnostic Laboratory
10.1.2.1. Market Revenue and Volume Forecast
10.1.3. Other
10.1.3.1. Market Revenue and Volume Forecast
11.1. North America
11.1.1. Market Revenue and Volume Forecast, by Biomarker
11.1.2. Market Revenue and Volume Forecast, by Diagnostic Technique
11.1.3. Market Revenue and Volume Forecast, by End-user
11.1.4. U.S.
11.1.4.1. Market Revenue and Volume Forecast, by Biomarker
11.1.4.2. Market Revenue and Volume Forecast, by Diagnostic Technique
11.1.4.3. Market Revenue and Volume Forecast, by End-user
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Volume Forecast, by Biomarker
11.1.5.2. Market Revenue and Volume Forecast, by Diagnostic Technique
11.1.5.3. Market Revenue and Volume Forecast, by End-user
11.2. Europe
11.2.1. Market Revenue and Volume Forecast, by Biomarker
11.2.2. Market Revenue and Volume Forecast, by Diagnostic Technique
11.2.3. Market Revenue and Volume Forecast, by End-user
11.2.4. UK
11.2.4.1. Market Revenue and Volume Forecast, by Biomarker
11.2.4.2. Market Revenue and Volume Forecast, by Diagnostic Technique
11.2.4.3. Market Revenue and Volume Forecast, by End-user
11.2.5. Germany
11.2.5.1. Market Revenue and Volume Forecast, by Biomarker
11.2.5.2. Market Revenue and Volume Forecast, by Diagnostic Technique
11.2.5.3. Market Revenue and Volume Forecast, by End-user
11.2.6. France
11.2.6.1. Market Revenue and Volume Forecast, by Biomarker
11.2.6.2. Market Revenue and Volume Forecast, by Diagnostic Technique
11.2.6.3. Market Revenue and Volume Forecast, by End-user
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Volume Forecast, by Biomarker
11.2.7.2. Market Revenue and Volume Forecast, by Diagnostic Technique
11.2.7.3. Market Revenue and Volume Forecast, by End-user
11.3. APAC
11.3.1. Market Revenue and Volume Forecast, by Biomarker
11.3.2. Market Revenue and Volume Forecast, by Diagnostic Technique
11.3.3. Market Revenue and Volume Forecast, by End-user
11.3.4. India
11.3.4.1. Market Revenue and Volume Forecast, by Biomarker
11.3.4.2. Market Revenue and Volume Forecast, by Diagnostic Technique
11.3.4.3. Market Revenue and Volume Forecast, by End-user
11.3.5. China
11.3.5.1. Market Revenue and Volume Forecast, by Biomarker
11.3.5.2. Market Revenue and Volume Forecast, by Diagnostic Technique
11.3.5.3. Market Revenue and Volume Forecast, by End-user
11.3.6. Japan
11.3.6.1. Market Revenue and Volume Forecast, by Biomarker
11.3.6.2. Market Revenue and Volume Forecast, by Diagnostic Technique
11.3.6.3. Market Revenue and Volume Forecast, by End-user
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Volume Forecast, by Biomarker
11.3.7.2. Market Revenue and Volume Forecast, by Diagnostic Technique
11.3.7.3. Market Revenue and Volume Forecast, by End-user
11.4. MEA
11.4.1. Market Revenue and Volume Forecast, by Biomarker
11.4.2. Market Revenue and Volume Forecast, by Diagnostic Technique
11.4.3. Market Revenue and Volume Forecast, by End-user
11.4.4. GCC
11.4.4.1. Market Revenue and Volume Forecast, by Biomarker
11.4.4.2. Market Revenue and Volume Forecast, by Diagnostic Technique
11.4.4.3. Market Revenue and Volume Forecast, by End-user
11.4.5. North Africa
11.4.5.1. Market Revenue and Volume Forecast, by Biomarker
11.4.5.2. Market Revenue and Volume Forecast, by Diagnostic Technique
11.4.5.3. Market Revenue and Volume Forecast, by End-user
11.4.6. South Africa
11.4.6.1. Market Revenue and Volume Forecast, by Biomarker
11.4.6.2. Market Revenue and Volume Forecast, by Diagnostic Technique
11.4.6.3. Market Revenue and Volume Forecast, by End-user
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Volume Forecast, by Biomarker
11.4.7.2. Market Revenue and Volume Forecast, by Diagnostic Technique
11.4.7.3. Market Revenue and Volume Forecast, by End-user
11.5. Latin America
11.5.1. Market Revenue and Volume Forecast, by Biomarker
11.5.2. Market Revenue and Volume Forecast, by Diagnostic Technique
11.5.3. Market Revenue and Volume Forecast, by End-user
11.5.4. Brazil
11.5.4.1. Market Revenue and Volume Forecast, by Biomarker
11.5.4.2. Market Revenue and Volume Forecast, by Diagnostic Technique
11.5.4.3. Market Revenue and Volume Forecast, by End-user
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Volume Forecast, by Biomarker
11.5.5.2. Market Revenue and Volume Forecast, by Diagnostic Technique
11.5.5.3. Market Revenue and Volume Forecast, by End-user
12.1. Abbott Laboratories
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Beckman Coulter Inc.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. BioMérieux
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. BioPorto Diagnostics AS
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. BIO-RAD LABORATORIES INC.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. F. HOFFMANN-LA ROCHE LTD.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Randox Laboratories Ltd
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. SEKISUI MEDICAL CO., LTD.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Siemens Healthineers AG
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Sphingotec GmbH
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample
Report Description
Get a Sample
Report Description